analysis. No correlation was present between the counts of herpesvirus-specific T cells and bacterial or fungal infections, possibly, as Th2 rather than Th1 T-cell response helps to curb bacterial infections.
The major limitation of our study is the relatively low number of patients. Additionally, we selected patients who did not have GVHD on day 56 (as these patients would not be candidates for withdrawal of immunosuppressive drugs or donor lymphocyte infusion (DLI)), and excluded patients who developed second malignancy (as these patients are typically treated by modalities that alter their immunity). We did evaluate the counts of herpesvirus-specific T cells in the six patients excluded owing to second malignancy (mostly post transplant lymphoproliferative disorder (PTLD)), but did not show the data. All patients had a score of 0. Even if these patients were treated with preemptive treatment for relapse (that is, withdrawal of immunosuppression or DLI), they would likely benefit from the treatment, as withdrawal or decrease of immunosuppression or DLI are treatment options for PTLD.
In conclusion, we have shown that herpesvirus-specific T cells can indeed be a surrogate marker of the GVL response in AML patients. The ability to predict patients with increased risk of relapse could lead to preemptive therapy, such as withdrawal of immunosuppression or DLI and reduction in relapse rates. However, preemptive therapy can have adverse effects. The ability to clearly distinguish between patients at high versus low risk of relapse is therefore essential. Our assay has shown a high sensitivity, however, a better specificity would be desirable for guiding preemptive treatment. Perhaps, if combining our assay with an assay of high specificity albeit poor sensitivity (for example, a minimal residual disease assay), the best prediction of relapse could be achieved. Future studies including a higher number of patients and performed prospectively are necessary to confirm the clinical utility of these assays.
The primary goal of initial therapy in acute myeloid leukemia (AML) is the effective and prompt achievement of complete remission without excessive morbidity and mortality, paving the way for post-remission strategies, including allogeneic stem cell transplantation. High-dose cytarabine (HiDAC) is an established component of most treatment regimens for adult AML and is incorporated into either the induction or consolidation phase of intensive chemotherapy. HiDAC-based consolidation therapy significantly improves the survival of adult patients with AML up to the age of 60 years. Attempts to further improve treatment outcomes in AML have led to studies investigating the role of HiDAC during AML induction. Randomized comparisons have consistently shown that HiDAC-based induction chemotherapy results in a higher complete remission rate after the first cycle of therapy, compared with standard dose ara-C induction. Complete remission rates of 77% after a single induction cycle can be achieved using HiDAC in combination with idarubicin and etoposide, compared with 41-66% with standard dose ara-C. [1] [2] [3] Although HiDAC-based induction achieves good early disease control, the benefits are offset by excessive induction-related toxicity and an increased risk of early death compared with standard dose ara-C. The definition of induction-related death varies widely between reports, making cross-study comparisons difficult. In patients under the age of 60 years, standard dose ara-C-based induction is associated with an early mortality rate of between 6-13%. [4] [5] [6] Early mortality after HiDAC induction ranges between 7-18%. 3, 4, [6] [7] [8] Identification of baseline risk factors predictive of early treatment-related mortality in adult AML after HiDAC-based induction therapy in a cooperative group setting has not been Letters to the Editor reported. A risk-stratified approach limiting HiDAC induction regimens to AML patients with a lower risk of early treatmentrelated mortality may be helpful in limiting factors that may contribute to iatrogenic death. This report identifies clinical variables associated with higher treatment-related mortality after HiDAC-based intensive chemotherapy in the Australasian Leukemia and Lymphoma Group (ALLG) AML M7 study.
Details of the ALLG AML M7 study have been previously reported. 3 In brief, 292 patients aged between 15-60 years, inclusive with de novo AML (excluding acute promyelocytic leukemia), received induction therapy with 'ICE', comprising idarubicin (9 mg/m 2 on days 1, 2 and 3), HiDAC (3 g/m 2 12-hourly on days 1, 3, 5 and 7), and etoposide (75 mg/m 2 daily on days 1 to 7 inclusive). Prophylactic anti-fungal therapy was with oral fluconazole 200 mg daily.
Criteria used for defining early death after induction chemotherapy in AML varies widely and lacks standardization. A plot depicting cumulative death after ICE induction revealed a rapid rate of early death, followed by a slower increase, with an apparent inflexion point between these two phases occurring around day 42, or 6 weeks ( Figure 1 ). The definition of induction mortality used in this study was therefore based on deaths occurring up to day 42 after commencing induction. No additional deaths were recorded in patients commencing consolidation therapy before day 42.
The initial 44 patients enrolled to the study received 12 mg/m 2 idarubicin for 3 days. This dose was revised to 9 mg/m 2 for 3 days for the remainder of the study by the ALLG safety and data monitoring committee, based on excessive early morbidity associated with this regimen. 3 A comparison of early death rates revealed no excess 42-day mortality from 12 mg/m 2 idarubicin (11.4%), compared with the subsequent 248 patients receiving the revised 9 mg/m 2 idarubicin dose (13.7%, P-value ¼ 0.67). The first 114 patients in the study were randomized to receive, or not, a daily dose of granulocyte colony-stimulating factor (lenograstim) after completing induction chemotherapy until neutrophil recovery. After patient 114, the protocol was amended such that the remaining 178 patients all received prophylactic granulocyte colony-stimulating factor. An assessment of early death during the period in which patients were randomly allocated granulocyte colony-stimulating factor during induction did not reveal significant differences between those receiving (13.8%) or not receiving prophylactic granulocyte colony-stimulating factor (11.7%; P-value ¼ 0.67), consistent with previously published randomized studies.
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Examination of early death rates stratified by age revealed that the risk of induction death was closely linked to increasing age. The 42-day mortality rate was 23% for those aged 50-60, compared with 2% or less for younger patients under the age of 30 years (Table 1 ). The risk of early death relative to baseline peripheral blood leukocyte count was also examined (Table 1) . Early induction mortality was substantially increased in patients with a presenting white cell count of greater than 100 Â 10 9 /l. Induction mortality in these patients was 27.6% by day 42, compared with only 4.8-13.1% for those presenting with lower levels of circulating leukocytes (Table 1) . Induction mortality was 6% in patients with a baseline Eastern Cooperative Oncology Group performance score of 0, compared with 17-33% for those with poorer performance status ( Table 1) . Of the 16 patients with an adverse risk karyotype, the induction death rate was 31.3%, compared with 6.8% for patients with favorable risk and 12.7% for those with intermediate cytogenetic risk AML (Table 1) .
A Cox proportional hazards regression analysis of prognostic factors associated with 42-day mortality after ICE induction identified five factors with independent adverse significance on both univariate and multivariate analysis: age 50-60, white cell count 4100 Â 10 9 /l, Eastern Cooperative Oncology Group 40, poor cytogenetic risk and elevated serum creatinine (Tables 2  and 3 ). Kaplan-Meier survival analysis showed that patients lacking these five independent risk factors for early death had a 3-year overall survival rate of 60% compared with 48% for patients presenting with at least one of these factors (Supplementary Figure S1 ). Fever at diagnosis did not emerge as an independent adverse risk factor, but was found to be strongly correlated with impaired performance status and a high leukocyte count (P ¼ 0.003 and 0.001, respectively).
Age over 50, which comprised 34% of the study population, was associated with an early death rate of 23%, highlighting older age as a key adverse prognostic factor for both early treatment-related and longer-term overall survival. A comparison of potential factors contributing to the increased risk of Table S1 ). There were, however, significantly more patients aged 50-60 with a performance score greater than zero (62.6%), compared with those under the age of 50 years (43.5%; P ¼ 0.002). The negative impact of age was also observed in an earlier Southwest Oncology Group study, in which the risk of induction death was 20% in those over the age of 50 receiving HiDAC, compared with 14% in younger patients. 7 The current analysis of risk factors for induction death after HiDAC-based induction chemotherapy in adult AML highlights the need for particular caution in patients over the age of 50 and in those with extreme hyperleukocytosis, adverse karyotype, impaired performance status and abnormal renal function. Hyperleukocytosis is an established poor prognostic factor in AML linked to increased early mortality after induction chemotherapy. 10 In this study, HiDAC administration to patients with extreme hyperleukocytosis (4100 Â 10 9 /l) resulted in early death in almost onethird of patients. Although emergency leucopheresis may reduce early mortality in patients with hyperleukocytosis, clinical proof that this practice is superior to chemotherapy is lacking.
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Although the current study had only 16 patients with poor risk karyotype, the 31% early death rate in these patients after HiDAC induction was substantial. The low complete remission rate (44%) and poor overall survival in adverse cytogenetic risk patients receiving HiDAC suggests that novel alternative approaches are urgently needed for this difficult AML sub-population.
In patients with abnormal renal function, the risk of induction death after HiDAC in this study was increased (33.3 versus 10.9%, P ¼ 0.01). Cerebellar toxicity has been reported to occur in 55% with renal impairment, compared with 7% in those with normal renal function, with risk virtually eliminated by the practice of reducing the dose of cytarabine to 1 g/m 2 twice daily in patients with baseline or emergent renal dysfunction. 12 The finding in this paper of increased early mortality after HiDAC induction in association with renal impairment supports cytarabine dose reductions in this situation.
Improvements in supportive care, especially the use of broadspectrum antifungal prophylaxis may allow intensive induction chemotherapy strategies to be delivered more safely. In May 2010, the ALLG completed accrual of 442 adult patients with AML treated with ICE induction (ALLG AML M12). This study will provide further important information regarding the ability to safely deliver HiDAC-based induction chemotherapy in the context of a modern supportive care environment.
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Prognostic factor
Hazard ratio Myeloma is a plasma cell dyscrasia, which is categorized as a B-cell neoplasia. It is usually incurable with a median survival period of 3-4 years. There are serious problems in treating patients with myeloma. Myeloma cells themselves are not merely less sensitive to chemotherapy due to their dormancy but prone to becoming drug resistant. The incidence of myeloma increases with age and the median age at diagnosis is B70 years. Currently, several new agents, such as bortezomib, lenalidomide and thalidomide, are clinically available for single or combined use for induction and maintenance. However, results have not been satisfactory with regard to overall survival and event-free survival. Thus, new therapeutic options are needed for patients with myeloma. Myeloma cells show the strong expression of CD38, but no expression of CD19 on their surface, differing from other hematologic malignancies containing B-cell neoplasms. Generally, in normal hematopoiesis, CD38 expression on the cell surface is restricted to lineage-committed precursors. 1 According to gene chip profiling, the expression of mRNA for CD38 is restricted to the thymus, bone marrow and prostate, suggesting that CD38 is a feasible target for immunotherapy. Immunotherapy including antibody treatment acts on cells, which have not entered the cell cycle and is desirable for aged patients because of fewer adverse effects. Thus, we investigated whether the retroviral vector-mediated transduction of an anti-CD38-chimeric antigen receptor (CAR) gene, which we developed previously, 2 contributed to the abrogation of myeloma cells. Here we report that T-cell immunotherapy with the anti-CD38-CAR is quite effective in eliminating myeloma cells highly expressing the CD38 molecule.
Two myeloma cell lines (RPMI8226 and KMM1) were cultured in RPMI-1640 medium supplemented with 10% fetal calf serum at 37 1C. Primary myeloma cells obtained from bone marrow aspirate of patients, peripheral blood cells from healthy donors and those from a patient (Patient 5) in autologous settings were subjected to Ficoll-density centrifugation. Informed consent was obtained from all of these patients and donors. Patients with myeloma and donors were examined as approved by the institutional review board at Hiroshima University and Fukuyama Central Hospital. The retroviral vector construct consisting of green fluorescein protein, the transmembrane domain of CD8a, the intracellular domains of 4-1BB, CD3z and anti-CD38 single-chain variable domain (scFv) was reported previously. 2 Peripheral blood mononuclear cells stimulated with PHA-M and IL-2 were transduced in virus-conditioned medium with polybrene in a polypropylene tube coated with fibronectin by spinoculation. The addition of anti-CD38 antibody (CPK-H; MBL, Nagoya, Japan) was used to protect transduced T cells from auto-lysis through cross-linking of anti-CD38-CAR with intrinsic CD38, because activated T cells express CD38 on their cell surface. 2 Briefly, to increase the number of T cells with anti-CD38-CAR and maintain the viability of the cells, we replaced the medium containing the antibody (0.15 mg/ml) and IL-2 (200 IU/ml) every 4-5 days until 14 days post-transduction. For the co-culture experiment, T cells were washed with phosphate-buffered saline and complete medium several times to eliminate the effect of residual antibodies in the medium. To detect surface expression of the anti-CD38-CAR, cells were stained with a goat anti-mouse (Fab') 2 polyclonal antibody conjugated to biotin followed by streptavidin-PerCP. Cytotoxicity of the transduced cells was assessed by flow cytometric analysis as described. 2 We had previously designed the retroviral vector carrying anti-CD38-CAR and green fluorescein protein genes. 2 T cells obtained from healthy donors were transduced with retroviral supernatant containing the anti-CD38-CAR vector. The anti-CD38-CAR was expressed with high efficiency. The median percentage of transduced cells was 65.89% (range, 48.98-89.98%; n ¼ 8). We confirmed the expression of the anti-CD38-CAR by flow cytometry using a goat-anti-mouse polyclonal antibody conjugated to biotin followed by streptavidin-PerCP, which reacts with the extracellular antibody-derived scFv of the anti-CD38-CAR (Figure 1a ). To assess their cytotoxicity, the T cells transduced with the anti-CD38-CAR were incubated with the KMM1 and RPMI8226 myeloma cell lines for 3 days at a variety of effector (E):target (T) ratios. The transduced cells exerted a highly cytotoxic effect on RPMI8226 cells in a timedependent manner ( Figure 1b) . As shown in Figure 1c , the chimeric receptor-mediated cytotoxicity was dose dependent. Table 1 shows the specific cytotoxicity of T cells with the anti-CD38-CAR to myeloma cell lines at an E:T ratio of 0.5:1.
